Updated safety and efficacy from the phase I study of givastomig, a novel claudin 18.2/4-1BB bispecific antibody, in claudin 18.2 positive advanced gastroesophageal carcinoma (GEC) Meeting Abstract
| Authors: | Klempner, S. J.; Shen, L.; Liu, D.; Dayyani, F.; Kratz, J.; Pan, H.; Liang, X.; Wang, Z.; Kim, S.; Deng, Y.; Deng, T.; Liu, T.; Girda, E.; Xu, C.; Nguyen, M. T.; Xia, J.; Wang, X.; Lee, S.; Jeon, J.; Ku, G. Y. |
| Abstract Title: | Updated safety and efficacy from the phase I study of givastomig, a novel claudin 18.2/4-1BB bispecific antibody, in claudin 18.2 positive advanced gastroesophageal carcinoma (GEC) |
| Meeting Title: | ESMO Congress 2024 |
| Journal Title: | Annals of Oncology |
| Volume: | 35 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2024 Sep 13-17 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2024-09-01 |
| Start Page: | S689 |
| Language: | English |
| ACCESSION: | WOS:001326612901321 |
| DOI: | 10.1016/j.annonc.2024.08.1076 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1017P -- Source: Wos |
